General Dermatology 

Eczema

Alopecia

Aesthetics

Vitiligo

COVID-19

Actinic Keratosis 

Precision Medicine and Biologics

Rare Disease

Wound Care

Rosacea 

Emerging Therapies Plaque Psoriasis

Treatments for Plaque Psoriasis 

Psoriasis 

Psoriatic Arthritis 

Biologic Treatments for Moderate to Severe Atopic Dermatitis 

Atopic Dermatitis 

Melasma

NP and PA

Skin Cancer (Nonmelanoma)

Skin Cancer

Hidradenitis Suppurativa

Drug Watch

Pigmentary Disorders 

Acne 

Pediatric Dermatology

Practice Management 

Prurigo Nodularis

News

Media

Around the Practice

Between The Lines

Case-Based Peer Perspective

Clinical Case Collective

DermView

Expert Perspectives

Fellows Face Off

Frontline Forum

Medical World News

Patient Perspectives

Podcasts

Readout360

Recognize and Refer

Conferences

Conference Coverage

Conference Listing

Events

Case-Based Roundtable

Publication

Dermatology Times

CME/CE

Resources

DermIQ

Interactive Tools

Job Board

Partner Perspectives

Polls

Editorial Advisory Board

Partners

Subscribe

Maddi Hebebrand is an associate editor of 

and joined the MJH Life Sciences team in May 2024. She attended Baldwin Wallace University, studying Media Production and Film, and is now finishing her Masters in Digital Media through Ohio University. When she's not writing, Maddi loves to read, attend concerts and spend time with her family.

Articles

The IL-13 inhibitor, recently FDA-approved for moderate to severe AD, reached all primary endpoints in the study focusing on patients with skin of color.

Lebrikizumab Shows Promise for Patients with Skin of Color and AD

Allie Karas is the vice president of content for the Health Care Specialty Group division of MJH Life Sciences. She attended Rider University and earned a degree in journalism before pursing a masters in magazine writing from New York University. Prior to making a switch to health care news in 2018, Allie spent 6 years in New York City working in political journalism. She enjoys spending time with her husband and 3 kids, cooking, working out, and her dog Bo. Follow her on Twitter at 

George Martin, MD, and Ted Rosen, MD, reprise their popular session on new therapies and products with a fast and furious rundown of the current armamentarium across disease states. 

New Treatments and Breakthroughs in Dermatology: Key Highlights From Maui Derm NP+PA Fall

At Maui Derm NP+PA Fall, Sheila Fallon Friedlander, MD, reviews key findings for the pediatric population from recent dermatology literature, covering topics like cutaneous Crohn’s disease, interrupting the atopic march, advancements in gene therapy, and more.

Pediatric Pearls From the Literature: Highlights From 2023 and 2024

and joined the MJH Life Sciences team in February 2023. She attended Kent State University and earned a Bachelor of Science degree in journalism with minors in public relations and creative writing. She enjoys making and listening to music, reading, and spending time with her cats, Astrid and Marceline.

The conference aimed at providing dermatology NPs and PAs clinicians with the latest updates in the specialty begins today in Nashville, Tennessee.

Previewing Maui Derm NP+PA Fall 2024: Will You Be There?

About

Advertise

Contact Us

Do Not Sell My Information

Terms and Conditions

Privacy Policy

Dermatology Times and Multimedia Medical, LLC

Twitter

Facebook

Linkedin

Topics

Acne

Pigmentary Disorders

Practice Management

Psoriasis

Psoriatic Arthritis

Rosacea

Neuroimmune Axis and Pruritus in PN

Pathophysiology of Prurigo Nodularis

Clinical Presentation and Pathophysiology of Prurigo Nodularis

Dermal Fibrosis in PN Infographic

Type 2 Inflammation and Chronic Pruritus in AD and PN

Contribution of Type 2 Cytokines in Chronic Pruritus in AD, PN, and CSU